Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022-Reference-Cited by-同舟云学术

Chapter 4: CKD treatment in cancer survivors, from Clinical Practice Guidelines for the Management of Kidney Injury During Anticancer Drug Therapy 2022

Published:2023-07-07 Issue:10 Volume:28 Page:1333-1342
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Ishikura Kenji,Omae Kenji,Sasaki Sho,Shibagaki Yugo,Ichioka Satoko,Okuda Yusuke,Koitabashi Kenichiro,Suyama Koichi,Mizukami Takuro,Kondoh Chihiro,Hirata Sumio,Matsubara Takeshi^ORCID,Hoshino Junichi,Yanagita Motoko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

https://link.springer.com/content/pdf/10.1007/s10147-023-02375-1.pdf

Reference70 articles.

1. Mayer DK, Nasso SF, Earp JA (2017) Defining cancer survivors, their needs, and perspectives on survivorship health care in the USA. Lancet Oncol 18:e11–e18

2. Matsuoka YJ, Okubo R, Shimizu Y et al (2020) Developing the structure of Japan’s cancer survivorship guidelines using an expert panel and modified Delphi method. J Cancer Surviv 14:273–283

3. Ministry of Health, Labour and Welfare in Japan (2021) Summary of Vital Statistics—Trends in leading causes of death. https://www.mhlw.go.jp/english/database/db-hw/populate/dl/E03.pdf. Accessed 3 March 2023

4. National Cancer Center in Japan (2007) Cancer Statistics in Japan ‘07—Cancer Prevalence Estimates (in Japanese). https://ganjoho.jp/data/reg_stat/statistics/brochure/2007/FIG21.PDF. Accessed 3 March 2023

5. Bluethmann SM, Mariotto AB, Rowland JH (2016) Anticipating the ‘Silver Tsunami’: prevalence trajectories and co-morbidity burden among older cancer survivors in the United States. Cancer Epidemiol Biomarkers Prev 25:1029–1036